TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer

CheckMate142: Checkpoint combination therapy in first-line colorectal cancer

SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer

Lung highlights from ESMO 2018

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC

Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Updates from the EMBRACA trial for advanced breast cancer

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer

Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer